The efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular blockage. A systematic review and network meta-analysis

Abdallah  Abunamoos; Amr  Elrosasy; Nada Ibrahim  Hendi; Obai  Yousef; Ahmad  Alzawahreh; Thoria Ibrahim Essa  Ghanm; Zina  Otmani; Mohamed Abouzid; Yehia  Nabil

doi:10.20883/medical.e1172

Authors

Abdallah Abunamoos School of Medicine, University of Jordan, Amman, Jordan
Amr Elrosasy Faculty of Medicine, Cairo University, Cairo, Egypt
Nada Ibrahim Hendi Faculty of Medicine, Ain Shams University, Cairo, Egypt
Obai Yousef Faculty of Medicine, Tartous University, Tartous, Syria
Ahmad Alzawahreh Faculty of Medicine, The Hashemite University, Zarqa, Jordan
Thoria Ibrahim Essa Ghanm Faculty of Medicine Mansoura University, Mansoura, Egypt
Zina Otmani Faculty of Medicine, Mouloud Mammeri University, Tizi Ouzou, Algeria
Mohamed Abouzid Poznan University of Medical Sciences https://orcid.org/0000-0002-8917-671X
Yehia Nabil Faculty of Medicine, Zagazig University, Zagazig, Egypt

DOI:

https://doi.org/10.20883/medical.e1172

Keywords:

Adamgammadex, Sugammadex, Neuromuscular block, NMB, Rocuronium

Abstract

Aim. We aim to evaluate the efficacy and safety of adamgammadex, a new modified γ-cyclodextrin, in reversing rocuronium-induced neuromuscular blockade compared with sugammadex or placebo.

MAterial and methods. We comprehensively searched three electronic databases (PubMed, Scopus, and ScienceDirect) from inception until February 2024 to detect all randomised controlled trials comparing adamgammadex versus sugammadex or placebo. STATA software 17 and RevMan version 5.4 were used for network and pairwise meta-analyses, respectively. The study protocol was prospectively registered in PROSPERO (CRD42024516623).

Results. Five randomised controlled trials comprising 530 patients were included in our study. There was a statistically significant difference between adamgammadex and sugammadex compared to placebo in the recovery time of neuromuscular function. A dose-response relationship was observed except for adamgammadex 7 mg/kg, which ranked first. Sugammadex was found to be more effective than a similar dose of adamgammadex. There was a non-significant difference between adamgammadex and sugammadex compared to placebo in the incidence of adverse events.

Conclusions. Adamgammadex or sugammadex can be a safe and effective therapeutic option in reversing rocuronium-induced neuromuscular blockade. More clinical trials with larger sample sizes should be conducted to obtain better evidence regarding these two drugs' most effective and safe doses.

Downloads

Download data is not yet available.

References

Griffith HR (1944) The Use of Curare in An æsthesia and for Other Clinical Purposes. Can Med Assoc J 50:144–147

Bruintjes MH, van Helden EV, Braat AE, et al (2017) Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis. Br J Anaesth 118:834–842. https://doi.org/10.1093/bja/aex116

Murphy GS (2018) Neuromuscular Monitoring in the Perioperative Period. Anesth Analg 126:464–468. https://doi.org/10.1213/ANE.0000000000002387

Sundman E, Witt H, Olsson R, et al (2000) The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology 92:977–984. https://doi.org/10.1097/00000542-200004000-00014

Murphy GS, Szokol JW, Marymont JH, et al (2008) Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 107:130–137. https://doi.org/10.1213/ane.0b013e31816d1268

Hayes AH, Mirakhur RK, Breslin DS, et al (2001) Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia 56:312–318. https://doi.org/10.1046/j.1365-2044.2001.01921.x

Debaene B, Plaud B, Dilly M-P, Donati F (2003) Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 98:1042–1048. https://doi.org/10.1097/00000542-200305000-00004

Kent NB, Liang SS, Phillips S, et al (2018) Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double-blind, placebo-controlled, randomised volunteer study. Anaesthesia 73:1079–1089. https://doi.org/10.1111/anae.14386

Bom A, Bradley M, Cameron K, et al (2002) A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl 41:266–270. https://doi.org/10.1002/1521-3773(20020118)41:2<265::aid-anie265>3.0.co;2-q

Herring WJ, Woo T, Assaid CA, et al (2017) Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: A pooled analysis of 26 studies. J Clin Anesth 41:84–91. https://doi.org/10.1016/j.jclinane.2017.06.006

Baldo BA (2023) Allergic and other adverse reactions to drugs used in anesthesia and surgery. Anesthesiology and Perioperative Science 1:16. https://doi.org/10.1007/s44254-023-00018-2

Rahe-Meyer N, Fennema H, Schulman S, et al (2014) Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology 121:969–977. https://doi.org/10.1097/ALN.0000000000000424

QI You-mao, QI Ying-bei, YU Bao-chun, et al (2018) Screened adamgammadex for reversing rocuronium-induced neuromuscular blockade with greater safety. Chinese Journal of Pharmacology and Toxicology 32:515–527. https://doi.org/10.3867/j.issn.1000-3002.2018.07.002

Chen M, Zhang W, Wen J, et al (2015) Spectroscopy study on the interaction of γ-cyclodextrin and its two derivatives with rocuronium and vecuronium. Academic Journal of Second Military Medical University 36:507. https://doi.org/10.3724/SP.J.1008.2015.00507

Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71

Hutton B, Salanti G, Caldwell DM, et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162:777–784. https://doi.org/10.7326/M14-2385

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5:210. https://doi.org/10.1186/s13643-016-0384-4

Sterne JAC, Savović J, Page MJ, et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https://doi.org/10.1136/bmj.l4898

McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 12:55–61. https://doi.org/10.1002/jrsm.1411

New in Stata | Stata. https://www.stata.com/stata17/. Accessed 28 Mar 2025

RevMan. https://training.cochrane.org/online-learning/core-software/revman. Accessed 11 Oct 2023

Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135. https://doi.org/10.1186/1471-2288-14-135

Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634. https://doi.org/10.1136/bmj.315.7109.629

Zhang Y, Jiang Y, Lei Q, et al (2024) Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block. British Journal of Anaesthesia 132:45–52. https://doi.org/10.1016/j.bja.2023.10.022

Zhao Y, Chen S, Xie W, et al (2024) Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular blockade: A multicenter, randomized, phase IIb study. Clinical and Translational Science 17:e13691. https://doi.org/10.1111/cts.13691

Jiang YY, Zhang YJ, Zhu ZQ, et al (2022) Adamgammadex in patients to reverse a moderate rocuronium-induced neuromuscular block. British Journal of Clinical Pharmacology 88:3760–3770. https://doi.org/10.1111/bcp.15320

Zhao Y, Chen S, Huai X, et al (2021) Efficiency and Safety of the Selective Relaxant Binding Agent Adamgammadex Sodium for Reversing Rocuronium-Induced Deep Neuromuscular Block: A Single-Center, Open-Label, Dose-Finding, and Phase IIa Study. Front Med 8:. https://doi.org/10.3389/fmed.2021.697395

Jiang Y, Zhang Y, Xiang S, et al (2020) Safety, tolerability, and pharmacokinetics of adamgammadex sodium, a novel agent to reverse the action of rocuronium and vecuronium, in healthy volunteers. Eur J Pharm Sci 141:105134. https://doi.org/10.1016/j.ejps.2019.105134

Sen S, Sari S, Kurt I, Cobanoglu M (2014) The use of train of four monitoring for clinical evaluation of the axillary brachial plexus block. J Clin Monit Comput 28:243–249. https://doi.org/10.1007/s10877-013-9520-z

Murphy GS, Brull SJ (2022) Quantitative Neuromuscular Monitoring and Postoperative Outcomes: A Narrative Review. Anesthesiology 136:345–361. https://doi.org/10.1097/ALN.0000000000004044

Thilen SR, Weigel WA, Todd MM, et al (2023) 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology 138:13–41. https://doi.org/10.1097/ALN.0000000000004379

Tsur A, Kalansky A (2014) Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia 69:1251–1257. https://doi.org/10.1111/anae.12736

Samara E, Stamatiou K, Balanika M, et al (2021) The Effect of Sugammadex on Prothrombin and Activated Partial Thromboplastin Time. Cureus 13:. https://doi.org/10.7759/cureus.14521

Kopman AF, Yee PS, Neuman GG (1997) Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology 86:765–771. https://doi.org/10.1097/00000542-199704000-00005

Hunter JM, Sneyd JR (2024) Is adamgammadex the brother of sugammadex or the next generation of reversal agent? British Journal of Anaesthesia 132:15–17. https://doi.org/10.1016/j.bja.2023.11.006